Roche stops Swiss antibiotic production due to high costs

Roche is ceasing production of Rocephin, Switzerland's last domestically manufactured antibiotic, at its Kaiseraugst facility due to rising costs. The decision stems from increased production expenses, declining antibiotic prices, and intense generic competition, despite efforts by Swiss health authorities to prevent it. This move leaves Austria as the only remaining European antibiotic production site, highlighting concerns about reliance on Asian suppliers for active ingredients.